
Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY®
… For Adolescents 12 through 15 Years of Age COMIRNATY® is the first and only COVID-19 vaccine to be granted FDA approval for adolescents 12 […]
… For Adolescents 12 through 15 Years of Age COMIRNATY® is the first and only COVID-19 vaccine to be granted FDA approval for adolescents 12 […]
…. for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY® Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: […]
BioNTech values and respects valid intellectual property rights. BioNTech’s work is original, and we will vigorously defend it against all allegations of patent infringement. However, […]
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety […]
and Other Virus Variants Effectively Replenished after 3rd and 4th COVID-19 Vaccination 12 / 2022 Two vaccinations with Comirnaty do not lead to adequate antibody […]
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness […]
By Food and Agriculture Organization (FAO), World Organisation for Animal Health (OIE) and World Health Organization (WHO) As we enter the third year of the […]
Your Excellency President Macron,Excellency President Macky Sall,Excellency President Abdel Fattah Al-Sisi,Excellency President Kenyatta,Excellency President Buhari,Excellency President Saied,Excellency President Michel,Excellency President von der Leyen,Excellencies, dear colleagues, […]
Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Director-General of the […]
Two years into the pandemic, health systems are still facing significant challenges in providing essential health services. Ongoing disruptions have been reported in over 90% […]
The audio file of today’s information session on the objectives, functioning and progress of the mRNA vaccine technology transfer hub in South Africa is available […]
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy […]
– Important Insights for the Development of Antiviral Therapies A research team led by the Paul-Ehrlich-Institut examined the interaction between the Zika virus and the […]
WHO Director-General’s opening remarks at the media briefing on COVID-19 — 18 January 2022 The volcanic eruption near Tonga and subsequent tsunami requires an urgent […]
On 15 January 2021, a shipment of 1.1 million COVID-19 vaccines to Rwanda included the billionth dose supplied via COVAX. Together with our partners, COVAX […]
Copyright © 2022 | WordPress Theme by MH Themes